Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71182 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Ya-Hui Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Rollin School of Public Health, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes. Research Design and Methods We conducted a retrospective cohort study using the Clinical Practice Research Datalink (CPRD) Aurum. Initiation of metformin monotherapy (1998–2021) defined base cohort entry, and initiation of second‐line treatment (2013–2021) defined study cohort entry (time zero). After propensity score trimming, we applied inverse probability of treatment weighted Cox models to estimate the association between second‐line agents and time to insulin initiation. The secondary outcome was time to treatment modification, defined as the addition of or switch to another antidiabetic drug class.
Results
Our analytic cohort included 64 404 patients; 44% initiated DPP‐4 inhibitors, 36% insulin secretagogues, 18% SGLT‐2 inhibitors, 1% thiazolidinediones and 3% GLP‐1 receptor agonists. Over a mean follow‐up of 2.9 years, initiation of TZDs, DPP‐4 inhibitors, or SGLT‐2 inhibitors was associated with a lower risk of insulin initiation than initiation of insulin secretagogues (HR [95% CI]: 0.59 [0.43–0.83], 0.75 [0.69–0.80] and 0.62 [0.56–0.68], respectively). For treatment modification, the risk was higher among TZD and DPP‐4 inhibitor initiators, and slightly lower among SGLT‐2 inhibitor initiators and GLP‐1 receptor agonist initiators than among insulin secretagogue initiators.
Conclusion
This study provides real‐world evidence that TZDs, DPP‐4 inhibitors and SGLT‐2 inhibitors may offer an advantage over insulin secretagogues in delaying insulin initiation after metformin monotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Rollin School of Public Health, Emory University, Atlanta, Georgia, USA.
- Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada.
- Departments of Medicine and of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Departments of Pediatrics and of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada.
- Division of Endocrinology, Jewish General Hospital, Montreal, Quebec, Canada.
ORCID-Profile: Kristian B Filion
Zitieren
APA
Yu, Y. H., Zhang, Q., Zapata-Bravo, E., Platt, R. W., Reynier, P., Yu, O. H. Y., & Filion, K. B. (2026). Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71182
Vancouver
Yu YH, Zhang Q, Zapata-Bravo E, Platt RW, Reynier P, Yu OHY, et al. Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71182
BibTeX
@article{Yu2026,
author = {Yu, Ya-Hui and Zhang, Qi and Zapata-Bravo, Estefania and Platt, Robert W and Reynier, Pauline and Yu, Oriana H Y and Filion, Kristian B},
title = {Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71182}
}
EUVIMED